

## Zika virus (ZIKV) (strain Zika SPH2015) ZIKV-E/Envelope protein (His)

### General Information

Protein Construction:	A DNA sequence encoding the Zika virus (strain Zika SPH2015) E / Envelope (domain III) (ALU33341.1) (Val593-Lys699) was expressed with a polyhistidine tag at the C-terminus. Predicted N terminal: Val 593
Species:	ZIKV
Expression Host:	HEK293 Cells
Accession:	ALU33341.1
Molecular Weight:	13 kDa (predicted)

### QC Testing

Biological Activity:	Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
Purity:	> 90 % as determined by SDS-PAGE.
Endotoxin:	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.

### Preparation and Storage

**Reconstitution:**  
A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

**Stability & Storage:**

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

**Shipping:**

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

### Protein Background

Envelope of Zika virus is responsible for receptor binding and membrane. Analysis of the envelope protein of Zika, from Brazilian Zika SPH215 (KU321639), indicates predicted B and T cell epitopes in peptides that are consistent with those reported for dengue, YFYF and Japanese encephalitis. The envelope Domain II B cell epitope, to which much dengue non-neutralizing cross-reaction is attributed, is also conserved also in Zika virus, consistent with prior field observations of cross-reactivity with dengue and YF. Domain III of the Zika envelope protein, likely the

main specific neutralizing domain, is distinct from recent Brazilian dengue isolates and a recent Peruvian YF isolate (GQ379163), 76% of possible major histocompatibility complex class (MHC) I and MHC II binding peptides and potential B cell linear epitopes are unique to Zika virus.

### Reference

Basarab M, et al. Zika virus. BMJ. 2016 Feb 26;352:i1049.

Júnior VL, et al. Zika virus: a review to clinicians, Acta Med Port 2015 Nov-Dec;28(6):760-765L.

Zammarchi, et al. Zika virus infection in a traveler returning to Europe from Brazil, March 2015.

Arturo Galindo-Fraga, et al. Zika virus: A new epidemic on our doorstep. Rev Inves Clin.2015, 67: 329-32.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481